Ventripoint Diagnostics Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Hugh MacNaught
- Full Time Employees
- 10
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 18 Hook Avenue Toronto ON Canada M6P 1T4
- IPO Date
- Nov 9, 2005
- Website
- ventripoint.com
- Similar Companies
- Business
- VentriPoint Diagnostics Ltd. (TSXV:VPT, OTCQB:VPTDF) develops and commercializes AI-powered diagnostic imaging tools for monitoring patients with heart disease worldwide; its flagship product, VMS+, transforms standard 2D echocardiograms into accurate 3D models of all four heart chambers using proprietary Knowledge Base Reconstruction (KBR) technology, delivering MRI-equivalent volumetric measurements and ejection fractions with compatibility across all major echocardiography systems; additional applications target congenital heart disease, pulmonary hypertension, left and right heart failure, cardiotoxicity in oncology, and technically difficult imaging cases. The company, founded in 2004 and headquartered in Toronto, Ontario, Canada, operates primarily in North America, Europe, and the United Kingdom, with products deployed in major hospitals across these regions and expanding distribution efforts into South Asia. VMS+ offers point-of-care advantages including faster turnaround times, lower costs, greater patient comfort, and integration into existing clinical workflows via secure, institution-based IT systems. Recent developments include the release of VMS+3.2 and VMS+4.0, alongside CE Mark and Health Canada approvals for VMS+4.0, with supplemental FDA 510(k) submission data provided in early 2025 anticipating clearance response by February end; the company entered a collaboration with Providence Health Care Ventures in October 2025 to validate VMS+ at St. Paul's Hospital in Vancouver, aiming to reduce cardiac MRI demand and enhance diagnostics across care settings starting early 2026. Ongoing partnerships encompass progressing license agreements with Ascend Cardiovascular LLC for embedding VMS+ into their cardiovascular IT platforms, joint R&D from an August 2023 collaboration, and referrals from the Ollie Hinkle Foundation; Ventripoint recruited an industry advisor for valvular disease initiatives targeting the $9 billion structural heart market, launched a U.S. mid-west sales program with pricing updates and financing options post-FDA clearance, expanded its Reference Centre Program for clinical validation, and conducted a second closing on convertible debentures to fund commercialization and operations.
Company News
Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript
Ventripoint Provides Corporate Update and Announces Shareholder Videoconference Call
Ventripoint Announces Successful Completion of Annual Quality and Regulatory Audits
Ventripoint Closes First Tranche of Private Placement Financing and Engages Strategic Advisors to Accelerate Commercialization of VMS+™ Technology
UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening Platform
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging
Ventripoint Diagnostics Announces Cancellation and Re-Grant of Options, Grant of Annual Incentive Options and Private Placement
UniDoc Health and Ventripoint Diagnostics Sign MOU to Evaluate Scalable Remote Cardiac Assessment and Screening Platform
Ventripoint Strengthens Board with Appointment of MedTech Executive and Commercialization Leader Dr. Philip Toleikis
Ventripoint Issue Shares for Payment of Debenture Interest
Ventripoint Engages More Capital Ltd.
Ventripoint Diagnostics' VMS+ Technology Selected for World-First AI Cardiac Monitoring Study in Breast Cancer Patients
Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease
Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance
Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript
Ventripoint Provides Videoconference Link to Annual General Meeting and Corporate Update
Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement
Ventripoint Issues Shares for Payment of Debenture Interest
The $59B Quiet Shift Reshaping How Patients Access Care
Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology